Łukasz Zapała

MD, PhD, FEBU

Medical University of Warsaw
Country flagPoland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Purpose Cancer diseases and type II diabetes mellitus (DM2) are today among the major health problems, particularly in developed countries. DM2 has been historically suggested to protect against the development of prostate cancer (PCa). This study aimed to explore the mechanisms of this relation and assess its impact on treatment and prognosis for patients with PCa. Methods The consecutive literature search was performed using PubMed, Cochrane, and Google Scholar for papers published between 2015 and 2025. Results DM2 might reduce the risk of primary PCa development with a size effect depending on the duration of DM2. Patients with type 2 diabetes often exhibit low levels of testosterone and SHBG, which has been speculated to constitute a protective effect against PCa development. On the other hand, peripheral insulin resistance might be a protective factor, given its proliferation-promoting properties. What remains, however, the backbone element of the DM–PCa prevalence relation is metformin, which has been described to modulate PCa development through activation of AMPK kinase, reducing the c-MYC oncogene and disrupting the action of androgen receptors. Finally, DM constitutes a well-known predictor of worse surgical outcomes as well as radiotherapy toxicity. Conclusion DM is associated with a modestly lower incidence of prostate cancer, likely mediated by hormonal cross-talk and metabolic changes. Metformin may confer additional protection in a wide range of molecular mechanisms. Nevertheless, diabetes worsens treatment course—raising surgical morbidity and radiotherapy toxicity—necessitating tight metabolic control and thoughtful anti-diabetic drug selection.

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

We aimed to determine whether berbamine (BBM) would have an effect on retinyl acetate (RA)-induced cystometric and biochemical parameters, characteristic of bladder overactivity. BBM exhibits anti-inflammatory, anti-oxidant, and muscle-relaxant effects which could counteract pathophysiological mechanisms observed in overactive bladder (OAB) syndrome. The cohort of 60 rats was divided into 4 groups: I—control, II—RA group, III—BBM, and IV—group with the combination of RA + BBM. The cystometry, BBF, cardiovascular parameters and diuresis, the analysis of the cFos, and biochemical biomarker levels were analyzed 48 h after completion of BRB administration. The examined substance turned out to reverse the cystometric changes and c-Fos expression changes induced by RA when compared to the control group. There were no significant changes observed in the analyzed groups of animals MAP, HR, BBF, or UP. Importantly, BBM also turned out to reduce the level of OAB biomarkers present in urine (NGF, BDNF), urothelium (TRPV1, SNAP29, ATP, CGRP, or OCT-3), bladder detrusor muscle (VAChT, Rho kinase) as well as to reduce the exponents of oxidative stress (3-nitrotyrosine, malondialdehyde). The multifactorial explanation of the successful alleviation of the RA-induced detrusor overactivity makes the concept of incorporation of BBM in the OAB treatment promising for the future research.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (10)

Rafał Pęksa

Medical University of Gdansk

POLAND
View details

Piotr Dobrowolski

Professor (Associate)

Maria Curie-Skłodowska University

POLAND
View details

Andrzej Wróbel

Medical University of Lublin

POLAND
View details

Ewa Urbanska

Full Professor, Head of Department

Medical University of Lublin

POLAND
View details

Artur Wdowiak

head / associate profesor

Medical University of Lublin

POLAND
View details

Michał Kunc

Pathologist

Medical University of Gdansk

POLAND
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Marcin Misiek

-

POLAND
View details

Ilona Sadok

Assistant Professor

John Paul II Catholic University of Lublin

POLAND
View details

Jakub Kwiatkowski

Medical University of Warsaw

POLAND
View details